Hikma's strong first half puts firm on target for record year

摘要

The Jordanian company Hikma Pharmaceuticals, which listed in London last year, has reported pretax profits in the first six months of the year up by 9.5% to dollar 42.4 million, and diluted earnings per share of 17.2 cents, up by 2.9%. In the first half Hikma achieved revenue growth of 17.6% to dollar 154.9 million and received 82 product approvals, compared with 98 for the whole of 2005.Of the product approvals, seven were for ANDAs and will facilitate new product launches to help drive generic sales growth in the second half of the year. In the first half generic sales were down by 4.2%.